3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
3
Unknown
1
Suspended
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
20
Neoplasm Metastasis
4
Neoplasms
3
Melanoma
3
Thyroid Neoplasms
1
Thymus Neoplasms
1
Thrombosis
1
Thromboembolism
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Immune System Diseases
1
Hormone Receptor Positive Advanced Breast Cancer
1
Head and Neck Neoplasms
1
HER2+ Breast Cancer
1
Gastrointestinal Neoplasms
1
Estrogen Receptor-positive Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
ER Positive, HER2 Negative Breast Cancer
1
Colonic Neoplasms
1
Chordoma
1
Cardiovascular Diseases
1
Interventions
Paclitaxel
6
Carboplatin
6
Radiotherapy
5
olaparib
4
Surveys and Questionnaires
4
Cisplatin
4
Surgical Procedures, Operative
3
Sentinel Lymph Node Biopsy
3
Metformin
3
pembrolizumab
2
lenvatinib
2
durvalumab
2
dostarlimab
2
anlotinib
2
Reverse Transcriptase Polymerase Chain Reaction
2
Progesterone
2
Magnetic Resonance Spectroscopy
2
Injections
2
High-Energy Shock Waves
2
Hematologic Tests
2
Genetic Testing
2
Docetaxel
2
Blood Specimen Collection
2
Base Sequence
2
Amplified Fragment Length Polymorphism Analysis
2
vistusertib
1
serabelisib
1
pazopanib
1
palbociclib
1
onapristone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Endometrial Neoplasms
×
palbociclib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled